Caribou rises as FDA grants cancer therapy RMAT status, fast-track tag

Caribou Biosciences

29/11/2022 15:58

** Shares of drug developer Caribou Biosciences Inc  CRBU.O 
rise 3.4% to $8.8 
    ** U.S. FDA grants co's CAR-T therapy CB-010 Regenerative
Medicine Advanced Therapy (RMAT) and fast track designation in
treating relapsed or refractory large B cell lymphoma (LBCL),
and non-Hodgkin lymphoma (NHL), respectively 
    ** LBCL is a cancer type that forms in white blood cells
called lymphocytes, while NHL cancer type starts in lymphatic
system 
    ** RMAT designation expedites the development and review of
regenerative medicine therapies, offers sponsor companies early
interactions with the FDA 
    ** A fast track designation facilitates development and
expedites review of therapies with the potential to treat a
serious condition where there is an unmet medical need
    ** CRBU's treatment is made of T-cells, which are white
blood cells that have been genetically altered to make them
better able to spot and attack cancer
    ** Including session's gain, stock down 41.5% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))